A Broader Search for Hair Growth
Research into hair loss now reaches beyond familiar medicines, exploring targeted drugs, immune therapies, regenerative procedures, and ways to deliver treatments to the scalp. These approaches reflect a wider effort to address different parts of hair-follicle biology, but a promising mechanism does not by itself mean a treatment is ready for patients.
A 2025 review of hair-loss drug development surveys these emerging directions, including cell-based treatments and new topical delivery systems. It is a review of developing research, not a clinical guideline. Many candidates it discusses remain in clinical trials or preclinical study, and their safety, effectiveness, and availability may not be established.
For patients, the first step remains understanding why hair is thinning or shedding. Pattern hair loss, autoimmune alopecia, medication effects, and other causes may call for different approaches. At On The Spot Dermatology in Glenview, care is grounded in personalized medical and cosmetic dermatology, so treatment choices can be considered in light of a person's skin health and individual needs.
New research may expand future options, but it should not be confused with proven care or a promise of regrowth. A dermatologist can help weigh the diagnosis, available evidence, personal health factors, and potential risks before considering a treatment. For a broader overview of how emerging approaches may fit alongside established care, see innovations in hair restoration.
Start With the Cause of Hair Loss
Hair loss describes several conditions, and treatments depend on what is happening at the follicle. Androgenetic alopecia (AGA), or pattern hair loss, is influenced by genetics and hormones. Alopecia areata (AA) is an autoimmune condition in which immune activity attacks hair follicles. Other contributors can include thyroid problems, nutritional deficiencies, medications, stress, and other medical conditions.
For women with pattern hair loss, thinning often develops gradually around the part and crown while the front hairline remains largely preserved. Topical minoxidil is a well-supported first option, but there is no single treatment that suits everyone. A dermatologist can consider the pattern, health history, pregnancy plans, and personal goals when discussing care. Benefits may take months to appear and can diminish when treatment stops.
An assessment typically includes questions about when the loss began and how quickly it is progressing, along with a review of health conditions, medicines, and hair-care practices. The dermatologist examines the scalp and hair for patterns of thinning, breakage, inflammation, or scarring. Depending on the findings, blood tests or a scalp biopsy may help identify an underlying condition. The American Academy of Dermatology’s guidance on hair-loss diagnosis describes these steps.
Gradual thinning, sudden shedding, patchy loss, and scarring can point to different causes and call for different evaluations. An early assessment can help clarify whether treatment is needed and which options fit the diagnosis. At otsdermatology.com, dermatology care is personalized, so the evaluation can account for a patient’s individual health and treatment goals rather than assume one approach fits every pattern.
Research reviews can help explain emerging therapies, but they are not diagnostic guidelines. A clinician’s evaluation remains essential, particularly when hair loss is sudden, accompanied by scalp symptoms, or occurring alongside other health changes. The right plan starts with identifying the cause, then weighing likely benefits, risks, and the time required to see a response.
Established Treatments Still Matter
New treatments attract attention, but established options remain part of hair-loss care. Dermatologists match treatment to the cause and pattern: for pattern hair loss, they may recommend topical minoxidil or a prescription medicine for suitable patients. Alopecia areata may call for treatments that address immune activity, while hair loss linked to a medical condition or damaging hair practices may require addressing that cause.
Topical minoxidil is an established option for men and women with pattern hair loss. It can slow further loss or support regrowth, though response differs from person to person. The 2025 review reports that visible improvement commonly takes three to six months, with peak efficacy around 12 months, and that continued use is generally needed to maintain benefit. These timelines are averages, not a promise of results. Read more about established minoxidil treatment.
Finasteride is a prescription option for male-pattern hair loss. It reduces dihydrotestosterone (DHT) by inhibiting type II 5α-reductase, the enzyme involved in producing DHT. Possible sexual side effects should be discussed with a clinician; finasteride is not FDA-approved for women. Dutasteride, which acts on two forms of the enzyme, has been compared with finasteride in research but is not FDA-approved for hair loss in the United States. The review of current and emerging treatments distinguishes these established medicines from therapies still under study.
Benefits from minoxidil or finasteride may fade after treatment stops, and neither works for everyone. Low-level laser therapy is another option sometimes considered for hereditary hair loss, but evidence is limited and repeated sessions are needed. It is a device-based treatment, not a new drug or a proven replacement for medication.
At On The Spot Dermatology in Glenview, personalized care from healthcare providers can help patients weigh diagnosis, health factors, treatment preferences, possible risks, and realistic expectations. That discussion matters whether considering familiar treatments or following emerging research: a newer candidate is not automatically a better fit, and investigational approaches should not be treated as established care.
Options Beyond Topical Minoxidil
Alternatives to minoxidil depend on the type and cause of hair loss, as well as a person’s health and preferences. For pattern hair loss, a clinician may discuss prescription medicines such as finasteride for appropriate patients. Other options include low-level light therapy, platelet-rich plasma (PRP), or hair transplantation for selected patients. The American Academy of Dermatology’s treatment guidance stresses that there is no single treatment that suits everyone.
At On The Spot Dermatology, care is grounded in personalized evaluation by healthcare providers. That assessment can help distinguish pattern hair loss from other causes and weigh nonsurgical approaches, including PRP, against a surgical option such as transplantation.
Microneedling is also used or studied alongside treatments such as minoxidil or PRP. It creates tiny punctures in the skin and is typically performed in a clinical setting.
PRP Offers a Regenerative Option
Platelet-rich plasma (PRP) is made from a patient’s own blood. A sample is drawn and processed to concentrate its platelet-rich portion, which is then injected into areas of scalp thinning. Platelets release growth factors that may support follicle activity, although PRP is not a guaranteed way to restore hair.
Studies reviewed in the medical literature report potential improvements in hair density and thickness, but results differ among patients. Preparation methods, the amount injected, and treatment protocols vary, making it difficult to compare findings or predict an individual response. The American Academy of Dermatology’s guidance on PRP describes repeat injections as typical, while the 2025 review of developing hair-loss treatments emphasizes that protocols and outcomes can vary.
Immune Treatments Target Alopecia Areata
JAK inhibitors are treatments for a specific immune-related condition, not a general answer to hair loss. Alopecia areata occurs when immune activity attacks hair follicles, while androgenetic alopecia, or pattern hair loss, has different drivers. This distinction matters when weighing treatment: a medicine developed for alopecia areata should not be assumed to help pattern thinning.
A 2025 review describes three FDA-approved JAK inhibitors for severe alopecia areata: baricitinib and deuruxolitinib for adults, and ritlecitinib for patients aged 12 and older. These medicines interrupt immune signals involved in follicle attack. Approval applies to specified groups and diagnoses, so a dermatologist must confirm the condition and assess whether treatment is appropriate. The review of hair-loss drug development also distinguishes these established options from drugs still being studied for pattern hair loss.
Some people with severe alopecia areata experience substantial hair regrowth over months of treatment. The response is not guaranteed, and hair may be lost again after the medicine is stopped. A clinician can explain what outcomes are realistic and whether continued treatment may be needed.
JAK inhibitors also require careful review of possible harms. Reported concerns include infections, blood clots, and cardiovascular events, which can matter differently depending on a person’s health history and other medicines. In a Glenview dermatology practice such as On The Spot Dermatology, individualized evaluation and clinician guidance are central to discussing treatment choices, expected benefits, and risks. These immune therapies should remain distinct from investigational candidates being studied for androgenetic alopecia, which do not have the same disease-specific approval.
New Drug Candidates Target Follicle Biology
Researchers are testing treatments that act on specific signals involved in androgenetic alopecia (AGA), or pattern hair loss. These candidates are at different stages of development, and none should be treated as an established replacement for minoxidil or other current care. A 2025 review describes many approaches as investigational or preclinical, not approved hair-loss treatments.
Can topical treatments target androgen signaling?
Topical androgen-receptor candidates aim to affect androgen signaling closer to the scalp. Clascoterone (also known as Breezula) and pyrilutamide (KX-826) are among the drugs being studied for AGA. Their proposed local action does not establish that they are safer or more effective than existing treatments. The review lists them as investigational, not FDA-approved hair-loss therapies. Read more about topical anti-androgen candidates.
What other follicle signals are under study?
The Wnt/β-catenin pathway helps regulate follicle development and regeneration. JW0061 and KY19382 are being studied for their effects on this pathway, but the review describes them as preclinical candidates, not routine treatment options.
Other investigational approaches act on different parts of follicle biology. TDM-105795 is a topical thyroid-receptor agonist, while DLQ01 is a prostaglandin F2α analog. PP405 is being studied for its potential to affect lactate metabolism and activate hair-follicle stem cells. These approaches have distinct proposed mechanisms, and their development stages and supporting evidence differ.
The review describes PP405 as under clinical evaluation, and other supplied material reports early Phase 2a findings. Those initial signals need confirmation in further research. They do not establish how well the treatment works for patients, how long any benefit might last, or when it could become available. There is no reliable launch date. The research status and proposed mechanisms of these candidates are summarized in the 2025 review of hair-loss drug development.
For patients, the distinction between a treatment in development and one available for care matters. On The Spot Dermatology offers personalized medical and cosmetic dermatology care in Glenview, Illinois, where a provider can discuss options in the context of a patient’s diagnosis, health, and preferences. Waiting for an investigational drug is not a substitute for assessing established choices. A dermatologist can help set realistic expectations while research continues.
Cell Therapies and Exosomes Remain Uncertain
Cell-based hair treatments aim to support or restore follicle activity by using cells involved in hair growth, or by encouraging the scalp environment to support follicles. Approaches under study include dermal papilla cells, dermal sheath cup cells, and cells derived from adipose tissue. Early findings have drawn interest, but the methods and evidence differ, and many remain under clinical study rather than routine care. A 2025 review describes these approaches and their varied development status, while stressing that research-stage treatments should not be mistaken for established options (review of emerging hair-loss treatments).
Dermal papilla cells help regulate hair growth and cycling, which makes them a focus of regenerative research. A therapy using these cells has been described as being in Phase 1/2a trials for men and women with androgenetic alopecia, or pattern hair loss. That trial status signals investigation, not proof of lasting benefit or availability as routine treatment. At On The Spot Dermatology in Glenview, treatment planning is personalized to the patient’s needs; discussion of a proposed cell procedure should still account for its evidence and regulatory status.
The review also reports that Shiseido began offering an autologous dermal sheath cup cell procedure in Japan in July 2024. This country-specific report does not establish that the procedure is approved or routinely available in the United States. Availability in one country is not the same as evidence of effectiveness for all patients, or U.S. authorization for hair-loss treatment.
Exosomes, tiny structures involved in cell-to-cell signaling, are also being studied for possible effects on follicle activity. Promising laboratory and preclinical findings do not establish that an exosome treatment safely or effectively regrows hair in people. The review finds that human evidence is insufficient to determine efficacy and safety, and that longer-term research is needed. Claims in advertisements or clinic materials should therefore be distinguished from findings in well-designed clinical studies.
For patients considering these options, a dermatologist can help separate established care from experimental procedures and explain what is known, what remains uncertain, and whether a treatment is appropriate for the diagnosis. Cell-based procedures and exosome products should not be presented as proven or FDA-approved hair-loss treatments in the United States. On The Spot Dermatology’s patient-focused evaluation can help place emerging claims in context alongside the person’s health history, hair-loss pattern, and treatment goals.
Delivery Innovations and Personalization
A treatment’s delivery method can affect how well it reaches the scalp, how long it remains available, and how easy it is to use. Researchers are studying topical formulations, lipid nanoparticles, microneedles, controlled-release systems, and 3D-printed scaffolds as ways to address those practical challenges. These approaches remain under development, rather than established solutions for hair loss, as a 2025 review of emerging treatments explains.
For example, microneedles may carry an ingredient through the skin’s outer layer, while nanoparticles and controlled-release systems are being explored to improve delivery or sustain exposure. A delivery advance does not prove that the drug itself works, is safer, or suits a particular person. It also does not replace the need to assess the diagnosis and the evidence for the treatment being delivered.
Progress Without Promises
Research is expanding the range of approaches under study, from drugs aimed at follicle signals to regenerative treatments and new delivery methods. A 2025 review describes this growing field, while emphasizing that many candidates remain in preclinical research or clinical trials rather than established care (review of emerging hair-loss treatments).
For patients, the practical starting point remains a clear diagnosis. Hair loss can have different causes, and the right plan depends on the condition, personal health, treatment evidence, and possible risks. At On The Spot Dermatology in Glenview, individualized care from healthcare providers can help patients discuss options in the context of their skin and health needs.
New findings are worth following, but trial-stage therapies should not be mistaken for proven or readily available treatments. A dermatologist can help weigh current options and set realistic expectations, without asking patients to wait for an unapproved treatment or promising that any approach will restore all lost hair.
